Holen Sie sich die Stockscreener-App
14.54
1.56%
-0.23
Handel nachbörslich:
14.74
0.20
+1.38%
Schlusskurs vom Vortag:
$14.77
Offen:
$14.9
24-Stunden-Volumen:
432.90K
Relative Volume:
0.66
Marktkapitalisierung:
$1.34B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-56.88M
KGV:
-22.02
EPS:
-0.6604
Netto-Cashflow:
$-39.43M
1W Leistung:
-4.59%
1M Leistung:
-1.09%
6M Leistung:
+105.95%
1J Leistung:
+249.52%
1-Tages-Spanne:
$14.39
$14.92
1-Wochen-Bereich:
$14.31
$15.59
52-Wochen-Spanne:
$3.43
$15.79
Alpha Tau Medical Ltd Stock (DRTS) Company Profile
Firmenname
Alpha Tau Medical Ltd
Sektor
Branche
Telefon
-
Adresse
-
Compare DRTS vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DRTS
Alpha Tau Medical Ltd
|
14.54 | 1.34B | 0 | -56.88M | -39.43M | -0.6604 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alpha Tau Medical Ltd Stock (DRTS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-12-15 | Eingeleitet | Citigroup | Buy |
| 2023-04-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-04-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-04-08 | Eingeleitet | Piper Sandler | Overweight |
| 2022-04-04 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Alpha Tau Medical Ltd Aktie (DRTS) Neueste Nachrichten
Clinical Trial Progress Might Change The Case For Investing In Alpha Tau Medical (DRTS) - simplywall.st
Alpha Tau Medical Ltd Balance Sheet – FWB:H44 - TradingView
Debt to assets ratio of Alpha Tau Medical Ltd – FWB:H44 - TradingView
Net income of Alpha Tau Medical Ltd – FWB:H44 - TradingView
Alpha Tau Medical stock trades at USD 15.30 - AD HOC NEWS
Alpha Tau Medical (DRTS) Reports Early Trial Progress, Is The Premium Already Priced In? - simplywall.st
Alpha Tau Medical Ltd.(NasdaqCM: DRTS) added to S&P Global BMI Index - marketscreener.com
Alpha Tau Medical stock holds steady as investors await next results - AD HOC NEWS
How Early Cancer Trial Results Will Impact Alpha Tau Medical Stock (DRTS) - simplywall.st
Alpha Tau Medical Ltd stock hits 52-week high at 15.2 USD - Investing.com Australia
Alpha Tau’s Cancer Trials Keep Beating Expectations. Three Major Data Readouts Are Next. By FinanceWire - Investing.com
Alpha Tau's Cancer Trials Keep Beating Expectations. Three Major Data Readouts Are Next. - benzinga.com
DRTS Stock Gets A Pre-Market Boost – Retail Shrug Off Wider Q1 Loss Ahead Of Key Pancreatic Cancer Data Reveal This Week - Stocktwits
Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More (ORMP) - Seeking Alpha
Is Trial Enrollment Completion Altering The Investment Case For Alpha Tau Medical (DRTS)? - simplywall.st
Is IMPACT Pilot Enrollment Completion Reshaping The Investment Case For Alpha Tau Medical (DRTS)? - simplywall.st
Alpha Tau Medical stock hits 52-week high at 15.11 USD By Investing.com - Investing.com Australia
Alpha Tau Medical stock hits 52-week high at 15.11 USD - Investing.com
Alpha Tau: Approaching Massive Year-End; Pounding The Table On Potential GBM Breakthrough - Seeking Alpha
Alpha Tau Medical Ltd. Warrant (DRTSW) Key Financial Ratios – Valuation, Profitability & More - Value Research
Alpha Tau to Participate in September Investor Conferences - Alpha Tau Medical
H.C. Wainwright reiterates Alpha Tau Medical stock rating on trial enrollment By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Alpha Tau Medical stock rating on trial enrollment - Investing.com Nigeria
Alpha Tau Medical (DRTS) finishes pancreatic IMPACT study signup - Stock Titan
Alpha Tau’s pancreatic cancer study grows from 12 to 48 patients as enrollment closes - Stock Titan
Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions - Yahoo Finance
Alpha Tau Medical Ltd. Warrant (DRTSW) Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
Alpha Tau Medical Warrant (DRTSW) Rises 4.1% to $4.05 as Support HoldsStock Picks - careplusvn.com
Alpha Tau Medical (DRTS) officer schedules next stock sale under 10b5-1 plan - Stock Titan
Alpha Tau Medical (NASDAQ:DRTS) Sets New 1-Year HighHere's What Happened - MarketBeat
Alpha Tau Medical stock hits 52-week high at 14.79 USD - Investing.com
Alpha Tau’s Clinical Momentum Put Its Cancer Tech On The Map - Finimize
Price to sales forward of Alpha Tau Medical Ltd. – NASDAQ:DRTSW - TradingView
Price to earnings forward of Alpha Tau Medical Ltd. – NASDAQ:DRTSW - TradingView
Price to earnings forward of Alpha Tau Medical Ltd. – BOATS:DRTSW - TradingView
DRTS Stock Price, Quote & Chart - ChartMill
Is Alpha Tau Medical’s (DRTS) Steepening Loss Curve Reframing Its High-Risk Innovation Strategy? - simplywall.st
Alpha Tau Medical Ltd.: Fundamental Analysis and Financial Ratings | DRTS | IL0011839383 - marketscreener.com
Alpha Tau Medical (XTAE:DRTS) Cyclically Adjusted Price-to-FCF : (As of Aug. 15, 2026) - GuruFocus
Alpha Tau Medical (XTAE:DRTS) Shiller PE Ratio : (As of Aug. 21, 2026) - GuruFocus
DRTS Forecast — Price Target — Prediction for 2027 - TradingView
Q3 EPS Estimate for Alpha Tau Medical Decreased by Analyst - MarketBeat
Alpha Tau Medical Warrant (DRTSW) Surges 8.96% to $3.89 as Traders Target Key ResistanceTrend Continuation Trade - careplusvn.com
Alpha Tau Medical (NASDAQ:DRTS) Stock Price Down 5.4% Following Insider Selling - MarketBeat
Alpha Tau Medical (NASDAQ:DRTS) CFO Sells $248,220.00 in Stock - MarketBeat
H.C. Wainwright raises Alpha Tau Medical stock price target to $16 - Investing.com
Five Takeaways from AHNS 2026: Alpha DaRT in Combination with Immunotherapy for Advanced Head and Neck Cancer - Alpha Tau Medical
Finanzdaten der Alpha Tau Medical Ltd-Aktie (DRTS)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):